Investigational Drug Information for Tegafur
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Tegafur?
Tegafur is an investigational drug.
There have been 147 clinical trials for Tegafur.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Fudan University, Taiho Pharmaceutical Co., Ltd., and National Cancer Institute (NCI).
There is one US patent protecting this investigational drug and twenty-eight international patents.
Summary for Tegafur
| US Patents | 1,600 |
| International Patents | 28,084 |
| US Patent Applications | 4,260 |
| WIPO Patent Applications | 2,607 |
| Japanese Patent Applications | 250 |
| Clinical Trial Progress | Phase 3 (2013-06-01) |
| Vendors | 80 |
Recent Clinical Trials for Tegafur
| Title | Sponsor | Phase |
|---|---|---|
| Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. | Nanjing Geneseeq Technology Inc | Phase 2 |
Clinical Trial Summary for Tegafur
Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur
US Patents for Tegafur
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tegafur | See Plans and Pricing | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | See Plans and Pricing |
| Tegafur | See Plans and Pricing | Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same | Protalix Ltd. (Carmiel, IL) | See Plans and Pricing |
| Tegafur | See Plans and Pricing | Nuclear targeting sequences | Yeda Research and Development Co. Ltd. (Rehovot, IL) | See Plans and Pricing |
| Tegafur | See Plans and Pricing | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tegafur
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tegafur | Canada | CA2961033 | 2034-09-11 | See Plans and Pricing |
| Tegafur | European Patent Office | EP3192791 | 2034-09-11 | See Plans and Pricing |
| Tegafur | Japan | JPWO2016039408 | 2034-09-11 | See Plans and Pricing |
| Tegafur | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
